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THE MOLECULAR MECHANISMS OF ALZHEIMER’S DISEASE AND THE 
PROMISE OF NOVEL TARGETED THERAPIES 
HELEN HYEWON LEE 
ABSTRACT 
 Alzheimer’s disease is a common cause of dementia in the elderly population that 
is characterized by progressive neurodegeneration and decline in cognitive functions. 
Scientists do not yet fully understand the biological mechanisms that cause Alzheimer’s 
disease, making it increasingly difficult to develop targeted therapies that thoroughly 
address the responsible agents that lead to dementia and subsequently Alzheimer’s 
disease. There is currently no cure available to permanently stop the progression of or to 
reverse the damage due to Alzheimer’s disease. This study aims to provide an overview 
of the potential causes of Alzheimer’s disease and review the current pharmacological 
treatment options for addressing the symptoms of Alzheimer’s disease and emerging 
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 Neurodegenerative diseases are marked by degeneration of structure and function 
of the central or peripheral nervous system and can take shape in various forms. Common 
among neurodegenerative diseases is Alzheimer’s disease (AD), a form of dementia that 
causes problems in memory, thinking, and behavior. With a growing global prevalence of 
AD, there has been increasing urgency to research and develop targeted treatments for 
AD, especially those that can stop the disease from progressing. This literature review 
describes: AD prevalence and the theories that aim to understand its causes, current 
methods used to treat AD symptoms, and emerging treatments that seek to target specific 
mechanisms that are purported to be responsible for AD progression and resulting 
cognitive decline.  
Specific Objectives 
Specific aims of this thesis: 
1. To understand the molecular mechanisms and pathology of Alzheimer’s 
disease. 
2. Compare and understand the mechanisms of different types of novel treatments 
for Alzheimer’s disease. 
3. To explore the direction in which novel Alzheimer’s treatment is headed and 





Prevalence of Alzheimer’s Disease  
AD is the most common cause of dementia in the elderly population that is 
characterized by progressive neurodegeneration and decline in cognitive functions. AD as 
a cause of death has recently increased although deaths from other major causes have 
decreased significantly in recent years. In fact, the number of recorded deaths from AD 
has increased 145 percent between 2000 and 2017 while the number of deaths from heart 
disease, the leading cause of death, has decreased 9 percent. AD is the 6th leading cause 
of death in the U.S., currently affecting an estimated 5.8 million people in the U.S. This 
figure is projected to increase by threefold, rising to nearly 14 million by 2050 (Facts and 
Figures, n.d.). On a global scale, about 50 million have dementia and the total number of 
people with dementia is projected to increase to 152 million in 2050. As lifespans 
increase worldwide and the number of people living with dementia in low- and middle-
income countries rise, there is heightened urgency to deliver a cure for AD which 
continues to surge in prevalence  (Dementia, n.d.). This urgency has been apparent to 
world leaders and during the 2013 G8 summit, the G8 declared dementia a high priority 
challenge and agreed on key commitments, including setting the goal to find a cure or a 
disease-modifying therapy for dementia by (Presenting a Global Evidence Base for 
Dementia Friendly Initiatives | World Dementia Council, n.d.). Countries across the 
world focus on raising awareness, providing quality care, identifying potential risks, and 




Types of Alzheimer’s Disease 
There are two main categories of AD: early-onset and late-onset AD. About 5% 
or approximately 200,000 of the more than 5 million Americans with AD have early-
onset AD which occurs in affected individuals during their 40s and 50s (Younger/Early-
Onset Alzheimer’s, n.d.). The causes of early onset AD are not clearly understood, but 
most of these individuals have the sporadic form of AD which progresses in a similar 
way as it does in older people. About 10-15% of early-onset cases are attributed to 
mutations in three genes, amyloid precursor protein (APP), presenilin 1 (PSEN1), and 
presenilin 2 (PSEN2), that is inherited in an autosomal dominant pattern, meaning one 
copy of an altered gene is sufficient to cause AD. Familial Alzheimer’s disease (FAD) is 
a rare form of AD that makes up less than 1% of all AD cases. FAD is certainly linked to 
mutations in APP, PSEN1, and PSEN2, and at least two generations have AD in affected 
families. Patients with FAD show symptoms of disease in their 30s, 40s, and 50s, and so 
almost all cases of FAD are also considered early-onset. Finally, late-onset AD is the 
most common form of AD, generally occurring in people over the age of 65. The 
universal consensus is that the brain mechanisms that cause AD occur years before late 
onset symptoms appear.  
Clinical Signs and Symptoms Alzheimer’s Disease 
There is no single test to confidently diagnose dementia due to AD so physicians 
rely on a variety of approaches and tools to aid in its diagnosis. Some of these methods 
include obtaining family and medical history, gaining input from family members on any 
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changes in behavior or cognitive skills, conducting physical and neurological exams and 
cognitive tests, ruling out other potential causes of dementia by using blood tests and 
brain imaging, and relying on additional brain imaging tools to determine levels of beta 
amyloid which a hallmark characteristic of AD (“2019 Alzheimer’s Disease Facts and 
Figures,” 2019).   
The characteristic biological features of AD are the appearance of extracellular 
amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) in the intra-cellular 
environment, as well as the loss of synapses which contribute to progressive cognitive 
decline. While research provides details about the molecular pathogenesis of AD to a 
certain extent, little is known about the cause of AD (Hasegawa, 2016; Sanabria-Castro et 
al., 2017). Age is the most important risk factor for AD, with the prevalence of AD 
increasing after 65 years of age (“2019 Alzheimer’s Disease Facts and Figures,” 2019). 
Diagnosing AD has been a challenge as it is considered a dynamic disease. As recent as 
2011, the National Institute on Aging and the Alzheimer’s Association (NIA-AA) has 
provided new diagnostic criteria that characterizes AD into three clinical stages, 
preclinical, Mild Cognitive Impairment (MCI), and Alzheimer’s dementia (Albert et al., 
2011). In the preclinical stage, pathologic changes in the brain, which can be measured in 
CSF and imaging biomarkers, are believed to occur decades before AD without clinical 
symptoms becoming apparent.  MCI presents memory impairments that are greater than 
normal when accounting for age and education, but do not inhibit individuals’ 
independence. Additionally, MCI may or may not progress to Alzheimer’s dementia. 
Finally, in Alzheimer’s dementia, the cognitive and behavioral symptoms become severe 
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to the extent that they impair a person’s ability to function independently. It is important 
to recognize that this research framework is not based on clinical outcomes and rather 
focuses on biomarkers in living persons, and shifts the diagnosis from one based on 
symptoms to that based on biology (Jack et al., 2018).  AD is considered as a continuum 
and the guideline updates attempt to aid clinical diagnostic decisions by reducing 
subjectivity and clearly defining the different phases.   
Alzheimer’s Disease Biomarkers  
One of the earliest AD biomarkers includes hippocampal volumetry, which 
stemmed from the observation of declining hippocampal volume in patients with AD that 
advances in conjunction with dementia progression (Jack et al., 1992). More recently, it 
is purported that cortical thickness could be a more reliable, age-independent AD 
biomarker (Knopman et al., 2016). Other MRI techniques that are used for detecting 
biomarkers include ventricular volume, white matter tract integrity, functional MRI 
(fMRI) and activation paradigm-based fMRI (Caselli et al., 2017).  
Biochemical cerebrospinal fluid (CSF) biomarkers and imaging-derived 
biomarkers are also used to characterize the pathological changes of AD. CSF biomarkers 
are used to support MCI and AD diagnosis by looking at the levels of beta-amyloid 
peptide (Aβ), total tau (t-tau), and phospho-tau (p-tau) in CSF. These biomarkers align 
with the pathologic processes of Aβ42 aggregation and tau’s hyperphosphorylation and 
are used to support the clinical diagnosis of probable AD (Jack et al., 2010). AD patients 
demonstrate diminished levels of CSF Aβ42 levels with respect to healthy subjects. Aβ 
levels are the earliest biomarkers that exist as it is purported that CSF Aβ show abnormal 
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levels before subjective memory deficiency is reported (Dubois et al., 2016). Tau levels 
in CSF reflect the tau pathogenesis in the cerebral cortex, with both t-tau and p-tau 
concentrations increasing in CSF (Tapiola et al., 2009). Both are associated with the load 
of neurofibrillary tangles and correlate with neuronal damage and the severity of AD 
(Shaw et al., 2009).  
The first human trial of positron emission tomography (PET)-adapted amyloid 
ligand called Pittsburgh Compound-B (PiB) imaged Aβ-amyloid, a key molecular 
component of AD in living patients (Klunk et al., 2004). PiB can be used as a tracer in 
PET to detect the cerebral Aβ load and spatial distribution. Imaging studies with PiB-
PET show a positive correlation with amyloid plaque accumulation and cerebral load of 
PiB is inversely related to the levels of CSF Aβ (Kantarci et al., 2012). However, 
cognitively normal elderly individuals without genetic risk factors for AD may also 
present positive PiB signals and PiB-PET is only recommended when other signs of 
dementia are present. This discovery also launched the development of longer half-life 
amyloid ligands that make them more accessible to medical centers. Clinical analysis is 
separated into positive or negative relative to cerebral amyloid burden contrasted with the 
cerebellum, but there is weak correlation between cerebral amyloid and cognitive 
impairment. Tau-PET demonstrates topographical patterns of ligand distribution that 
correlate with clinical cognitive impairment (Ossenkoppele et al., 2016), and thus taken 




Autopsy studies of elderly patients who appeared clinically normal but showed 
moderate degrees of AD pathology in their brains suggested preclinical phase of AD 
(Katzman et al., 1988). The APOEε4 allele is a strong genetic risk factor for AD, and 
preclinical pathology was found to correlate with APOEε4 (Caselli et al., 2017). 
Fluorodeoxyglucose (FDG)-Pet studies of asymptomatic APOE 3ε4 carriers demonstrate 
abnormally low measurements of cerebral metabolic rate for glucose (CMRgI) in the 
same regions as patients with AD, effectively demonstrating metabolic patterns that 
parallel AD (Reiman et al., 2001). MRI studies show increased hippocampal atrophy 
prior to MCI diagnosis and longitudinal neuropsychological studies show quicker 
memory decline by an estimated 10 to 15 years in advance of MCI symptoms (Caselli et 
al., 2009, 2014). Amyloid ligands applicable for PET made it possible to show cerebral 
amyloid increase with age and its acceleration with gene dose by c (Fleisher et al., 2013). 
The Dominantly Inherited Alzheimer’s Disease Network is a study that pools members 
from kindreds with different genetic backgrounds sharing a disease that causes autosomal 
dominant mutation. DIAN has shown biomarker changes display a sequence of earliest 
change of declining CSF Aβ amyloid levels preceding predicted symptomatic onset by up 
to 25 years, with subsequent increasing CSF tau, increased cortical atrophy shown by 
MRI, waning cerebral metabolic glucose rates (CMRglucose) via FDG-PET, decreased 
memory scores, and decreased mental status scores 5 year before onset of observable 
symptoms (Bateman et al., 2012).   
PET imaging with 2-deoxy-2 [18F] fluoro-D-glucose tracer (FDG-PET) is used to 
measure glucose metabolism in the brain. FDG-PET is an indicator for neuronal and glial 
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function, with FDG-PET signal decreasing in AD (Jagust et al., 2007). This is consistent 
with glucose hypometabolism and synaptic dysfunction and correlates with decreased 
levels of post-mortem synaptophysin which indicates loss of synaptic activity. 
Individuals with AD also present bilateral reduction in FDG uptake in the temporal and 
parietal regions especially in the cingulate cortex (Scheltens et al., 2016). The ability to 
trace regional distribution and total tau burden with PET imaging lends to show tau-PET 
as a more sensitive marker for detection of early cerebral changes in AD compared to Aβ 
PET measures. FDG-PET studies confirm bilateral temporo-parietal hypometabolism is 
the metabolic abnormality associated with AD, and moreover suggest that in individuals 
with dementia with FDG-PET scans that show metabolic pattern different from bilateral 
temporo-parietal hypometabolism, should consider causes of dementia other than AD 
(Hoffman et al., 2000).  
FDG-PET scans thus have become a way to confirm AD diagnosis and 
differentiate AD from other dementias such as frontotemporal dementia and Lewy body 
dementia (Marcus et al., 2014). Additionally, FDG-PET has proved its value in meta-
analysis that showed FDG-PET’s greater diagnostic accuracy compared to other 
diagnostic methods such as clinical guidelines, MRI, CT, and SPECT (Bloudek et al., 
2011). This meta-analysis demonstrated FDG-PET’s pooled sensitivity (SN) of 91%, 
specificity (SP) of 86%.  Furthermore, FDG-PET has demonstrated its ability to 
differentiate patients with AD from normal subjects with SN of 99% and SP of 98%, 
from those with dementia with Lewy bodies (DLB) with SN of 99% and SP of 71%, and 
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patients with frontotemporal dementia (FTD) with SN of 99% and SP of 65% (Figure 1) 
(Mosconi et al., 2008). 
 
Figure 1. FDG-PET Images of AD. Cortical 18F-FDG-PET patterns in MCI, AD, FTD, and DLB. 3D-SSP maps show 
reduction in CMRglc in clinical groups compared with the NL database, on a color-coded scale ranging from 0 (black) 
to 10 (red). 3D-SSP maps show the right and left lateral, superior and inferior, anterior and posterior, and right and left 
middle views of a standardized brain image, from left to right (Mosconi et al., 2008).  
Alzheimer’s Disease Neuropathology 




Figure 2. Amyloid Plaques and Neurofibrillary Tangles in AD. A) Diffuse and neuritic plaques (Campbell-Switzer 
silver stain, middle frontal gyrus, 100x); B) neurofibrillary tangles (Gallyas silver stain, cerebral cortex, 100x) in AD 
patient (Caselli et al., 2017). 
Amyloid plaques are described as diffuse or neuritic, and while neuritic plaque density is 
significantly associated with cognitive impairment, there is weaker relationship between 
diffuse plaques and cognitive impairment. Plaque formation occurs when insoluble Aβ 
amyloid that causes dystrophic axons and dendrites react and contain pathological 
bundles of tau proteins identical to NFT’s found within neuronal perikaryal. Tau protein 
normally stabilizes microtubules in the neuronal cytoskeleton. Tau in dystrophic neurites 
and NFTs is abnormally phosphorylated, impairing microtubule binding and facilitating 
tau aggregation into paired helical filaments. This is thought to impair the neuron’s 
ability to maintain dendritic and axonal arborizations, which ultimately leads to loss of 
synaptic connectivity and neuronal death (Caselli et al., 2017).  
The sole presence of plaques and tangles is insufficient for AD diagnosis as they 
can be present in nondemented individuals. Therefore, neuropathological criteria aid in 
defining the likelihood that dementia is an outcome of AD. The 1985 NIA consensus 
panel recommendations focused on neocortical plaque density in relation to age 
(Khachaturian, 1985) and the 1991 Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) recommendation also focused on neuritic plaques (Mirra et al., 1991). 
Additionally in the early nineties, Braak and Braak demonstrated six stages of NFT 
pathology from pralimbic to neocortical regions occurring from earliest to the latest in the 
transentorhinal (stage I/II), limbic (stage III/IV), and neocortical (stage V/VI) (Braak & 
Braak, 1991, 1995).  NIA and Reagan Institute then combined CERAD amyloid plaque 
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and Braak NFT staging as: high likelihood includes frequent CERAD neuritic plaque 
score and Braak Stage V/VI NFT, intermediate likelihood includes moderate CERAD 
plaque score and Braak NFT stage III/IV, and low likelihood AD includes sparse 
CERAD plaque score and Braak NFT stage I/II (“Consensus Recommendations for the 
Postmortem Diagnosis of Alzheimer’s Disease. The National Institute on Aging, and 
Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological 
Assessment of Alzheimer’s Disease,” 1997). Amyloid plaque distribution, on the other 
hand, starts in the neocortical regions and builds through Braak stages IV and V with 
increasing subcortical and subsequent brainstem and cerebellar engagement (Thal et al., 
1998).    
 Other neuropathological signs of AD include reduced hippocampal and 
amygdalar atrophy, where the rate of hippocampal atrophy is higher in individuals with 
AD compared to those with MCI and the healthy elderly who also exhibit hippocampal 
atrophy over time (den Heijer et al., 2010). Ventricular enlargement is also observed in 
individuals with AD, which becomes increasingly apparent due to the co-existing 
reduction in brain volume. While hippocampal atrophy and ventricular enlargement is 
most significantly observed in individuals with AD, they also occur in the normal elderly 
independent of AD pathology. Therefore, these two factors are recommended to be 
included as covariate in hippocampal and ventricular analysis (Apostolova et al., 2012) 
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THE MOLECULAR MECHANISMS OF ALZHEIMER’S DISEASE 
Cholinergic Hypothesis 
Substantial research and investigation of the biochemical system of brains of 
patients with AD began in the 1960s and 1970s with the hope of identifying 
neurochemical abnormalities which could inform the development of therapeutic targets. 
Acetylcholine (ACh) is the neurotransmitter used by all cholinergic neurons, which play 
significant roles in the central and peripheral nervous system. ACh is used as 
neurotransmitter in all pre- and post-ganglionic parasympathetic neurons and all pre-
ganglionic sympathetic neurons. Additionally, part of the post-ganglionic sympathetic 
neurons also uses ACh as neurotransmitter. Cholinergic neurons innervate almost all 
regions of the brain, suggesting their prevalence in mediating significant functions 
(Woolf & Butcher, 2011). Reports of substantial neocortical deficits in the enzyme 
choline acetyltransferase (ChAT), which is responsible for the synthesis of ACh and 
reduced choline uptake (Rylett et al., 1983) as well as the degeneration of cholinergic 
neurons from the nucleus basalis of Meynert (Whitehouse et al., 1981, 1982) provide 
evidence for presynaptic cholinergic deficit. Thus, these studies accompanied by 
evidence of the significant role of ACh in learning and memory support the “cholinergic 
hypothesis of Alzheimer’s disease”.  
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Cholinergic deficit may be related to cytoskeletal dysfunction in AD. Aβ is toxic 
to cholinergic cells and affects cholinergic neurons in numerous ways as summarized in 
Figure 3 (Pákáski & Kálmán, 2008).   
Figure 3. Aβ’s Effects on Cholinergic Neurons. Schematic portrayal of various changes in cholinergic neurons due to 
A(Wang et al., 2016)β (Pákáski & Kálmán, 2008). 
ACh neurotransmission is dependent on proteins needed for synthesis, transport, 
degradation and reuptake. ACh is synthesized in the cytoplasm of cholinergic cells where 
the enzyme choline acetyltransferase (ChAT) catalyzes the reaction of dietary choline 
and Acetyl-CoA to form ACh. Transfer of ACh to synaptic vesicles is aided by the 
vesicular acetylcholine transporter (VAChT). Depolarization of cholinergic neurons 
enables the release of ACh by exocytosis into the synaptic cleft. Then, ACh activates 
both muscarinic and nicotinic receptors on the post synaptic neuron. Nicotinic 
acetylcholine receptors (nAChR) are ion gated channels that are selective for cations 
including sodium, potassium, and calcium. Nicotinic receptors are made up of a 
combination of five different subunits which influence the properties and functions of the 
different nicotinic receptors. While nicotinic receptors are mostly located on the post 
synaptic neuronal membrane in the peripheral nervous system (PNS) where they are 
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activated by ACh to facilitate the transfer of signals, the receptors in the central nervous 
system (CNS) are mostly located on the pre-synaptic neuronal membrane where their 
activation regulates the release of acetylcholine and other neurotransmitters into the 
synapse. Activation of ACh receptors results in increase in calcium levels in the 
presynaptic neuron, a crucial step in the exocytosis of gamma aminobutyric acid 
(GABA), glutamate, dopamine, and serotonin into the synapse. Muscarinic receptors are 
G-protein coupled receptors whose role is mainly in transmission of signals. Muscarinic 
receptor isoforms M1, M3, and M5 are excitatory and their activation results in formation 
of second messengers by phospholipase C which results in closure of K+ channels which 
then enables greater depolarization of the cell and transmission of signal down the axon. 
M2 and M4 isoforms are inhibitory and their activation result in the inhibition of adenylyl 
cyclase which leads to lower levels of cyclic adenosine monophosphate (cAMP) and 
promotes inhibition of [Ca]++ channels diminishing cell excitability. In the synaptic cleft, 
the enzyme acetylcholinesterase (AChE) breaks down ACh into its components Acetyl-
CoA and choline. The choline transporter, CHT1, then facilitates the uptake of choline 
into the presynaptic neuron. CHT1 is also the source of the choline used in acetylcholine 
synthesis and therefore plays a crucial role in recycling acetylcholine (Ferreira-Vieira et 
al., 2016).  
Studies have shown reduced ChAT activity in the amygdala, hippocampus and 
cortex of patients with AD and reduced levels of AChE, suggesting decreased levels of 
ACh (Davies & Maloney, 1976). In addition to the decreased activity of enzymes 
responsible for ACh synthesis, levels of ACh uptake by neurons in the frontal cortex and 
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the hippocampus were significantly lower in patients with AD. Additional indication of 
loss of cholinergic function in the uptake of choline is seen in lower levels of presynaptic 
high affinity choline uptake carrier (HACU) in the cortex and hippocampus (Pascual et 
al., 1991; Rylett et al., 1983).  
The majority of cholinergic neurons in mammalian brains reside in the basal 
forebrain nuclei and send cholinergic projections primarily to the hippocampus, 
neocortex, and amygdala (Ballinger et al., 2016). Cholinergic signaling from the basal 
forebrain to the hippocampus is imperative to learning and the formation of spatial 
memories as evidenced by the effect of elevated ACh levels on hippocampal plasticity in 
performance in spatial memory tasks (Roland et al., 2014; Wallenstein & Vago, 2001). 
Conversely, the loss of neurons in the nucleus basalis of Meynart is correlated with 
impairments to memory and learning, which further supports the cholinergic hypothesis 
(Friedman, n.d.; Lo Conte et al., 1982).  
Amyloid Cascade Hypothesis 
The amyloid cascade hypothesis, which formally dates back to 1992, postulates 
that the deposition of Aβ plaques in the parenchyma of the brain is a key step that causes 
AD (Hardy & Higgins, 1992). Specifically, the hypothesis credited dementia to neuronal 
cell death caused by toxic insoluble amyloid fibrils. Aβ is formed when a main form of 
APP, a 695 amino acid membrane protein, is cleaved by BACE (β-site APP-cleaving 
enzyme) and then further cleaved by γ-secretase to yield Aβ. BACE processes APP at the 
N-terminal domain while γ-secretase acts on the APP transmembrane domain  through 
endopeptidase/carboxypeptidase cleavages. This cleavage at variable sites yields Aβ 
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peptides of varying length, including Aβ40 and Aβ42 which are the most common forms 
found in the human brain (Zhang et al., 2014). Aβ monomers then oligomerize with each 
other and form Aβ peptides that are postulated to accumulate and have neurotoxic effects 
(Haass & Selkoe, 2007; Lambert et al., 1998; Wilquet & Strooper, 2004). Arguments 
supporting the amyloid cascade hypothesis include examples of AD pathogenesis of 
individuals with autosomal-dominant mutations in genes encoding APP or γ-secretase 
complex proteins PSEN1 and PSEN2. Additionally, the substantial number of patients 
with Down syndrome with early clinical manifestation of AD is credited to triplication 
and overexpression of gene coding for APP on chromosome 21 (Ricciarelli & Fedele, 
2017).  
The Aβ oligomer hypothesis postulates that soluble Aβ oligomers (AβOs), even in 
the absence of amyloid fibrils or larger aggregates such as senile plaques, are the toxins 
that target and disrupt particular synapses to cause memory impairment (Ferreira & 
Klein, 2011). Staining with oligomer-specific antibody has demonstrated AβO 
association with neurons in a scattered manner early in AD, prior to the presence of 
amyloid plaques (Figure 4). This suggests that synaptic disruption may be the cause for 
AD and neuronal loss may account for impaired memory and brain function in later 
stages of AD.  
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Figure 4. Aβ Oligomers in AD. Aβ oligomers elevated extracellularly around neurons in AD cortex. Sections from the 
frontal cortex of the AD brain were stained using oligomer-specific antibody. Stain is associated with dendritic arbor 
and display its scattered association with individual neurons in early AD. Adapted from (Lacor et al., 2004) 
Aβ-deposition appears to follow a sequence in which affected regions are 
hierarchically involved. It appears Aβ deposits are initially found in the neocortex. Then, 
in a second phase, allocortical brain regions, diencephalic nuclei, stratum, and cholinergic 
nuclei of the basal forebrain display Aβ deposits. As Aβ deposition progresses, brainstem 
nuclei become involved followed by cerebellar Aβ deposits (Thal et al., 2002). In vivo 
amyloid-PET imaging studies have also demonstrated the regional pattern of progressive 
and hierarchical amyloid deposition (Grothe et al., 2017). Dominantly inherited AD can 
be caused by variants of the APP gene (St George-Hyslop et al., 1987), PSEN1 
(Schellenberg et al., 1992), and PSEN2 (Levy-Lahad et al., 1995) which all impact 
cerebral amyloid production or aggregation. PSEN1 and PSEN2 encode the active site of 
γ-secretase. Additionally, the Aβ theory is further supported by evidence of gene coding 
mutation (A673T) in the APP gene that reduces the formation of amyloidogenic peptides 
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in vitro by approximately 40%, and protects against AD and cognitive decline in elderly 
individuals without AD. This suggests that reducing the β-cleavage of APP may protect 
against AD (Jonsson et al., 2012).  
Tau 
 Tau protein is a cytoskeletal microtubule-associated protein that aids in the 
assembly of tubulin to microtubules. These proteins are expressed in many neurons 
which develop axons and dendrites for neuronal transmission, which explains the 
implications for abnormal tau protein in cognitive degeneration. The tau gene is localized 
in the 17q21 region on the long arm of chromosome 17 in humans. Six tau isoforms are 
expressed in the adult human brain due to mRNA alternative splicing, with or without 
exons 2, 3, and 10 (Multiple Isoforms of Human Microtubule-Associated Protein Tau: 
Sequences and Localization in Neurofibrillary Tangles of Alzheimer’s Disease: Neuron, 
n.d.). Exon 10 insertion leads to 4-repeat (4R) tau isoforms, while 3-repeat (3R) tau 
isoforms are produced without exon 10. Tau is primarily localized in axons, but 
phosphorylated tau can be apparent in the somatodendritic compartment. Tau is highly 
soluble in water and stable at high heat which can be manipulated to purify tau easily 
from E. coli, cultured mammalian cells, and brain tissues (Goedert & Jakes, 1990; Iqbal 
et al., 2016). Tau accumulates in a hyperphosphorylated state in the pathological 




Figure 5. Tau Tangle Formation in AD. High-level process of Tau tangle formation in AD progression shows 
hyperphosphorylated tau leading to destabilization of microtubule and subsequent tau tangle formation. Adapted from 
(Kumar et al., 2018).  
It appears as a filament-structure, paired helical filaments (PHFs), which are fibrils of 
10nm diameter and 80nm periodicity (Hasegawa, 2016b). These filaments are referred to 
as NFTs when formed in neuronal cell bodies, and threads when formed in dendrites or 
axons. Observations of abnormal tau in frontotemporal lobar degeneration (FTLD), 
which occurs in frontotemporal dementia, show PHFs that are highly phosphorylated at 
~20 serine/threonine residues outside the microtubule binding region. Pathological 
insoluble PHF-tau proteins can be separated into six tau isoforms after 
dephosphorylation, indicating that abnormal phosphorylation may likely be the cause of 
assembly and deposition of PHF.  
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 Although the Aβ pathology is considered relatively specific to AD and dementia, 
tau abnormalities are seen in neurodegenerative diseases such as Pick’s disease, 
progressive supranuclear palsy, and corticobasal degeneration. This does not discount the 
significance of tau proteins in AD as post-mortem analyses of human brains demonstrate 
characteristic progression of Aβ plaques and regular patterns of NFT. Aβ plaque 
progression of appearance is correlated with the function and anatomy of the affected 
brain regions.   
Genetics of Alzheimer’s Disease 
 AD has a significant genetic component and its understanding has become a 
critical part in the efforts to define the pathophysiological causes and progression of AD. 
Beginning in the 1980s, the systematic linkage between genes and AD was developed. 
Particularly, the three genes encoding APP on chromosome 21, PSEN1 on chromosome 
14, and PSEN2 on chromosome 1, were found to be largely responsible for early onset, 
dominantly inherited forms of AD (Cacace et al., 2016). A biological child of a mother or 
father carrying a genetic mutation for one of the three genes has a 50/50 chance of 
inheriting the mutation, which leads to the child having strong probability of developing 
early-onset AD. AD also affects about 30% of people with Down syndrome in their 50s 
and about 50% of individuals with Down syndrome in their 60s (“Alzheimer’s Disease & 
Down Syndrome,” n.d.). It is believed that the chances of developing AD are higher 
among these individuals because they have an extra copy of chromosome 21 which 
carries the APP gene. There is still a lot scientists do not know about the specific 
mechanisms of early-onset AD and additional research is warranted to determine other 
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genetic variants that may be involved in other cases of early-onset AD, both sporadic and 
familial.  
While the majority of AD cases appear to be late-onset, sporadic forms, with no 
clear signs of hereditary influence, AD is has a high level of heritability at about 70%, 
which is similar to that of schizophrenia (~80%) and above diabetes (~50%) and 
Parkinson’s disease (~30%) (Gatz et al., 2006; Lyon & Hirschhorn, 2005; Warner & 
Schapira, 2003). The apolipoprotein E (APOE) is a main cholesterol carrier that encodes 
for three protein variants that are all involved in lipid transport in the brain and APOE 
itself has three alleles. The risk of developing AD is highly dependent on which allele is 
inherited. APOEε2 is the rarest allele and plays a protective role, showing that it may 
reduce the risk of developing AD by up to 40%. APOEε3 is the most common allele and 
it does not affect the risk of developing AD. APOEε4 increases the risk of developing AD 
and lowers the age of onset of AD. Having one copy of APOEε4 can increase the risk of 
AD by 2 to 3 times while two copies of APOEε4 increases the risk by 12 times 
(Michaelson, 2014). APOE is synthesized by astrocytes and microglia and plays a role in 
the formation of Aβ plaques. APOE4 protein is believed to increase the risk of AD by 
preventing the clearance of Aβ peptides and promotes Aβ aggregation (Kim et al., 2009).  
After the APOEε4 allele was associated with the risk of developing AD, there 
were limited breakthroughs in our understanding of genetics and AD until genome-wide 
association studies (GWASs) allowed researchers to study thousands of individuals and 
millions of genetic variations. In 2009, other genetic risk factors were considered with 
help from high-throughput genomic approaches. Namely, the first two large-scale 
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GWASs led the discovery of three new genetic risk factors: CLU, CR1 and PICALM 
(Harold et al., 2009; Lambert et al., 2009). To date, more than 40 genes/loci have been 
associated with the risk of developing AD, but more comprehensive and diverse genetic 
studies are necessary to analyze and clarify existing genetic findings. One of the specific 
areas generating increased interest is the role of microglia in AD. Triggering receptor 
expressed on myeloid cells-2 (TREM2) is a gene whose expression is restricted to 
microglia in the brain, and has demonstrated to increase the risk of developing late-onset 
AD. Amyloid-associated myeloid cells derive from microglia in the brain rather than 
being recruited from peripheral blood monocytes. TREM2 may play a distinct functional 
role at different stages of AD pathology where TREM2 deficiency ameliorates amyloid 
pathology by reducing cell proliferation thereby reducing plaque-associated myeloid cell 
accumulation. However, in the late stages of AD progression, TREM2 deficiency 
decreases inflammation-related gene transcript levels (Jay et al., 2017).  TREM2 has been 
postulated to play a protective role because AD-associated mutations (R47H, R62H) 
potentially impair TREM2 functions. In TREM2 absence, Aβ plaques do not become 
fully enclosed by microglia and are more dispersed and less dense, which is associated 




Figure 6. Impaired Microglial Response to Aβ Deposits in the Absence of Trem2. Microglial response to Aβ 
plaques in 4-month-old 5XFAD, Trem2+/- 5XFAD, and Trem2-/- 5xFAD mice. Comparable cortical regions are stained 
with X-34 (red) for amyloid plaques, lba-1 (white) for microglia, and To-pro3 (blue) for nuclei (Wang et al., 2016).  
This suggests that TREM2 plays a protective role by allowing microglia to surround and 
Aβ plaque to limit diffusion and amyloid-related neuronal damage (Wang et al., 2016).  
Evidence also suggests various AD risk variants may be in microglial-specific enhancers, 
which regulate gene expression, sometimes in a cell-dependent way (Nott et al., 2019). 
AD appears to be regulated by genetic variants within microglial cells, which further 
supports the importance of microglia in AD.  
Alternative Theories for Alzheimer’s Disease 
 One theory for what accounts for AD stems from the similarities seen between 
lysosomal storage in brains of people with lysosomal storage disorder and brains of 
people with AD. For example, both conditions share similarities including storage of 
failed lysosomal bodies, plaques and neurofibrillary tangles. However, lysosomal storage 
disorder symptoms show up weeks after birth and are fatal in a few years while AD 
occurs primarily in old age. Given this time difference, it’s postulated that long-lived 
proteins may become problematic, undergoing spontaneous modifications, making them 
 
24 
undigestible by lysosomes (Lambeth et al., 2019). The fundamental structure of the 
amino acids making up the proteins may change, which makes it difficult for lysosomal 
enzymes that typically break down the protein to proteolytically cleave the peptide bonds 
and digest the protein.   
Pharmacological Treatments for Alzheimer’s Disease  
Currently, no treatments are available to cure AD or stop the progression of AD. 
Rather, current treatments focus on helping people manage their cognitive, functional, 
and behavior symptoms and slowing down the symptoms of AD. The U.S. Food and 
Drug Administration (FDA) has approved two types of medications, cholinesterase 
inhibitors and memantine, or the combination of the two, to treat the cognitive symptoms 
of AD (How Is Alzheimer’s Disease Treated?, n.d.). There are currently five FDA 
approved drugs that fall into these categories. The cholinesterase inhibitors include 
donepezil, galantamine, and rivastigmine, which are used to treat symptoms related to 
thinking, language, judgment, and other processes. The other two drugs include 
memantine, which appears to work by modulating the activity of glutamate, and a 
combination of memantine and donepezil. Most prescription drugs work best for those 
with early to middle stages of AD.  
Cholinesterase inhibitors comprise the most established strategy in the treatment 
of AD. Cholinesterase inhibitors work by inhibiting the acetylcholinesterase thereby 
inhibiting the breakdown of ACh, which plays a vital role in learning and memory. This 
treatment is in line with the cholinergic hypothesis of AD. For treatment of mild to 
moderate AD, there are currently three FDA-approved cholinesterase inhibitors on the 
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market – galantamine, rivastigmine, and donepezil. Specifically, cholinesterase inhibitors 
block the activity of AChE thereby increasing the levels of ACh in the brain. While 
galantamine and donepezil are cholinesterase inhibitors, rivastigmine is a reversible 
inhibitor of ACh and butyrylcholinesterase (BChE). Galantamine binds to nicotinic 
cholinergic receptors and has also been used to treat myopathy, myasthenia as well as 
sensory and motor deficits associated with the CNS (de Souza et al., 2011). Rivastigmine 
is also used to treat dementia associated with Parkinson’s disease. Rivastigmine’s exact 
mechanism of action is unclear but rivastigmine tartrate targets BChE and AChE.  
Donepezil acts at the neurotransmitter level and at the molecular and cellular level, 
including inhibition of glutamate-induced excitotoxicity, reduction of early expression of 
inflammatory cytokines, induction of neuroprotective isoform of acetylcholine and 
reduction of oxidative stress-induced effects (Jacobson & Sabbagh, 2008). They also 
appear to have other benefits, namely, galantamine may stimulate the release of 
acetylcholine by stimulating nicotinic receptors and rivastigmine blocks the monomeric 
(G1) form of AChE with greater selectivity compared to the tetrameric (G4) form, which 
could be beneficial in the treatment of AD (Jann, 2000). It also has noncholinergic effects 
and is expected to increase hepatic clearance of Aβ and prevents Aβ from crossing the 
blood brain barrier (Mohamed et al., 2015).  
Memantine is approved for moderate to severe AD. Memantine is an N-methyl-d-
aspartate (NMDA) receptor antagonist that is believed to work by blocking excessive 
NMDA activity by acting as an uncompetitive, low-affinity, open-channel blocker. It 
works by regulating glutamate to inhibit excessive influx of calcium that is induced by  
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chronic NMDA receptor activation (Robinson & Keating, 2006). Glutamate, an 
excitatory neurotransmitter found in the brain and spinal cord, is considered to play a 
significant role in learning processes. In AD, glutaminergic neurons are overactivated and 
release more glutamate compared to non-AD conditions. Specifically, memantine works 
by “uncompetitively” blocking the ionotropic NMDA receptor (NMDAR) (Parsons et al., 
2007). Ionotropic receptors are formed by multiple proteins coupled to an ionic channel 
where the activation of the receptor triggers the opening of the ion channel and allows 
cations or anions to enter or leave the cell. Memantine blocks the open ion channel in a 
way similar to Mg2+, blocking the ion flow, namely Ca2+ through the channel. When there 
is excess glutamate, NMDAR activity increases which results in increased inflow of Ca2+ 
which results in excitoxicity that can lead to neuronal injury or neuronal death. In 
addition to having a role in neuronal death, hyperactive NMDARs are also associated 
with neurofibrillary degeneration and tau toxicity associated with AD (Chohan & Iqbal, 
2006; Degerman Gunnarsson et al., 2007). Memantine may have a dual action (Figure 7) 
where it may also inhibit the internal ribosome entry site (IRES) in addition to being an 
NMDAR antagonist. Specifically, memantine has been observed to inhibit IRES-
mediated translation initiation in COS-1 cells which prevents APP expression and tau 
proteins, which may relieve AD symptoms (Dominguez et al., 2011). Memantine is also 
believed to enhance neuronal synaptic plasticity of the brain at lower doses, improving 
memory and protecting against neuronal destruction caused by excitatory 





Figure 7. Dual Mechanism of Memantine on AD. Memantine blocks the NMDA receptor which results inhibits 
neurotoxicity associated with excess glutamate (1). Memantine may also inhibit IRES which inhibits Tau and APP 
proteins (2). Adapted from (Dominguez et al., 2011). 
LITERATURE REVIEW 
The studies cited in this thesis were primarily discovered by searching for articles 
using the PubMed database including, but not limited to, the following terms or 
combination of terms: Alzheimer’s disease, cognitive impairment, Aβ, tau, 
neurodegeneration, neuropathology, Alzheimer’s pharmacology, Alzheimer’s treatment, 
immunotherapy, gene therapy, biomarkers.  
Significant research has been conducted to identify therapeutic targets and 
therapeutic agents to treat AD. Currently, pharmacological agents are being used to 
alleviate some of the psychiatric symptoms of AD. However, these treatments do not 
provide a cure. There has been ongoing research in immunotherapy and gene therapy to 
treat AD. This thesis focuses primarily on the potential for immunotherapy and gene 
therapy to be used to treat AD.  
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Immunotherapy for Alzheimer’s Disease  
The amyloid cascade hypothesis postulates that the deposition of Aβ plaques in 
the parenchyma of the brain is a key step that causes AD. This idea has guided 
pharmaceutical research in the recent past, including immunotherapies targeting Aβ. Aβ 
immunotherapy, which has been heavily investigated and touted as one of the most 
promising ways to treat AD, relies on the use of synthetic peptides or monoclonal 
antibodies (mAb) to decrease the Aβ load in the brain to slow the progression of the 
disease. This was proposed in 1999 as a potentially effective way in preventing and 
treating AD after immunization of PDAPP transgenic mice, which overexpress mutant 
human APP and develop several AD-like lesions, demonstrated prevention of Aβ 
formation in young mice and reduction in the extent of progression of AD-like 
neuropathologies in older mice (Schenk et al., 1999). In theory, Aβ appears to be a 
logical target in humans because active and passive amyloid immunization demonstrated 
increased clearance of amyloid deposits and improved cognitive performance in AD 
transgenic mouse models (Dodart et al., 2002). Furthermore, observations show that 
patients with AD have lower levels of naturally occurring anti-Aβ antibodies in the CSF 
and blood than is normally found in elderly individuals, suggesting the potential 
significance of supplementing anti-Aβ to treat AD (Du et al., 2001; Weksler et al., 2002). 
The initial human active immunization trial (AN1792) used full length Aβ42 as 
the immunogen, but the Phase II trial resulted in unanticipated autoimmune 
meningoencephalitis with correlated cerebral edema in 6% of participants, which led to 
the trial’s suspension (Gilman et al., 2005; Orgogozo et al., 2003). Long-term follow up 
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of patients who were immunized with AN1792 showed detectable, sustained anti-
AN1792 antibody titers in patients who were labeled as responders in the phase 2a study. 
These responder patients did not have significantly different brain volume loss compared 
to patients who received placebo treatment, but they did demonstrate significantly 
reduced decline in cognitive function, supporting the hypothesis that immunotherapy 
with Aβ antibodies could provide long-term benefits (Vellas et al., 2009). Other 
examinations demonstrated patchy plaque removal, largely indicating potential of an 
immunomodulatory approach and contributing to the launch of passive immunization 
strategies (Nicoll et al., 2003; Patton et al., 2006). The initial passive anti-Aβ 
immunotherapy for AD treatment focused on bapineuzumab, which is comprised of 
humanized anti-Aβ monoclonal antibodies. In two Phase II trials, bapineuzumab reduced 
Aβ burden in the brains of AD patients, but failed to improve clinical outcomes (Anti-β-
Amyloid Immunotherapy for Alzheimer’s Disease: Focus on Bapineuzumab - PubMed, 
n.d.; Salloway et al., 2014).  
Despite ongoing research, several therapeutic agents that aim to reduce the 
production or accumulation of the Aβ peptides have failed to show benefit in Phase III 
clinical trials in established, early disease. Passive immunization with bapineuzumab and 
solanezumab, another mAb that targets epitopes of Aβ amyloid, demonstrated 
engagement with molecular targets and improvement in surrogate biomarkers, but neither 
reduced the degree of cognitive or functional decline in symptomatic participants  
(Doody et al., 2014; Salloway et al., 2014). Secondary analysis of the solanezumab trial 
patients with mild stage AD seemed to show 34% reduction in rate of progression across 
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18 months but later reports from a phase 3 trial in mild stage AD proved unsuccessful  in 
producing a similar outcome (Siemers et al., 2016). Failure in demonstrating efficacy of 
these immunotherapies has led to reconsideration of existing disease models as well as 
diagnostic and therapeutic strategies. Additionally, Aβ-targeted immunotherapy has been 
limited by other challenges including development of encephalitis and lack of effect on 
NFTs.  
Tau pathology is mainly intracellular and would be a less feasible immunotherapy 
target although NFTs play a central role in dementia. Nevertheless, passive immunization 
in mouse models have demonstrated positive results in limiting AD progression 
(Sankaranarayanan et al., 2015). Additionally, active immunotherapy that targets tau 
epitope phosphor-Ser422 resulted in tau clearance and improved cognitive deficits due to 
tau in transgenic mouse models (Troquier et al., 2012).  
Considerable research has also been conducted on intravenous immunoglobulin 
(IVIG) as another therapeutic strategy. IVIG comprises the use of a mix of IgG 
antibodies from the plasma of healthy volunteers. IVIG has been found to contain higher 
levels of antibodies against Aβ monomers and aggregates (Dodel et al., 2002; Szabo et 
al., 2010). In preclinical studies, IVIG appeared neuroprotective against toxic effects of 
Aβ in vitro and improved microglia-mediate Aβ clearance ex vivo, while reducing 
inflammation in transgenic mice in vivo (Magga et al., 2010; Sudduth et al., 2013).   
Despite successful Phase I and Phase II trials, IVIG failed to significantly slow cognitive 
and functional decline as a result of AD in the Phase III Gammaglobulin Alzheimer’s 
Partnership (GAP) study (Relkin, 2014).  
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Some believe failed immunotherapy trials have done “too little too late” in terms 
of the timing of intervention and that there may be success if treatment is started earlier. 
By mild to moderate dementia stages, amyloid levels plateau and deficits are driven by 
tau pathology. Thus, if amyloid no longer drives the disease process, intervention in those 
stages may indeed be too late (Hyman, 2011). Despite setbacks, research progress has led 
to better understanding of AD’s preclinical phases, development of imaging and 
biomarkers for early detection and disease progression tracking, especially before 
symptoms present themselves, as well as AD genomics. Targeting asymptomatic patients 
whose cerebral amyloid levels are gradually rising will require greater understanding of 
the preclinical phase and biomarker tracking that can assess potential therapeutic 
effectiveness, which both require ongoing research that may provide additional evidence 
to show whether immunotherapies may be beneficial in treating AD.  
Gene Therapy and its Applications for Alzheimer’s Disease 
Gene therapy is an experimental method for treating disease by targeting and 
altering an individual’s genetic material. Most commonly, gene therapy works by 
inserting a healthy copy of a defective gene into a patient’s cells using adeno-associated 




Figure 8. Schematic of Gene Therapy. Viral vectors are used to transfer genetic material in order to allow the healthy 
copy of the gene to enter the cell and deposit the genetic material. Adapted from (Gene Therapy, n.d.) 
Gene therapy can be used to treat both inherited and acquired genetic diseases. In AD, 
current gene therapy studies focus on the APOE gene. AD mouse model studies have 
concluded that APOE knockout mice and APOE2 targeted replacement mice that have 
AD-defining Aβ plaques showed decreased amyloid burden and reduced brain soluble 
and insoluble Aβ levels after being injected with AAV delivering the APOE2 gene 
variant (Zhao et al., 2016). The results from this study demonstrate how APOE2 gene 
delivery can ameliorate the damaging effects of APOE4 on brain amyloid pathology. As 
expected, there are ongoing clinical trials that are testing the viability of this therapeutic 
approach for treating or preventing AD by aiming to achieve sufficient levels of APOE2 
in the brain early in AD progression. The same team that published the findings from the 
mouse model study with APOE knockout mice and APOE2 targeted replacement mice is 
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currently conducting a clinical trial, “Gene Therapy for APOE4 Homozygote of 
Alzheimer’s Disease” which is designed to evaluate gene therapy in patients who are 
APOE4 homozygotes with mild cognitive impairment to very mild to severe dementia 
from AD. The study is assessing the safety and toxicity of intracisternal administration of 
an AAV gene transfer vector that expresses the cDNA encoding APOE2 (Gene Therapy 
for APOE4 Homozygote of Alzheimer’s Disease - Full Text View - ClinicalTrials.Gov, 
n.d.). Additionally, gene therapy method for AD with AAV knockdown of CD33 (Siglec-
3), a transmembrane sialic acid-binding receptor on the surface of microglial cells, was 
shown to reduce Aβ accumulation and neuroinflammation (Griciuc et al., 2020). In this 
case, the AAV vector-based system that encodes artificial microRNA targeting CD33 
(miRCD33) was injected intracerebroventricularly into APP/PS1 mice. This was most 
effective in reducing Aβ burden in when intervening early at 2 months rather than 8 
months in mice. Additionally, early intervention appeared to downregulate microglial 
receptor transcripts and pro-inflammatory activation genes. Post-mortem AD patient 
brains show upregulation of CD33 in microglial cells. High levels of CD33 inhibit uptake 
and clearance of Aβ in microglial cell cultures, and thus the study indicates that CD33 is 
a potential target for AAV-based knockdown methods that can reduce AD pathology and 
progression. Additionally, proof of concept of AAV-based delivery of single domain 
antibodies (VHH) in a mouse model of cerebral amyloidosis demonstrated significant 
reduction in Aβ levels, further indicating the potential of using VHH as novel, effective 
therapeutics (Rincon et al., 2019).   
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In addition to gene therapies, there are three commonly used gene editing tools 
currently available to researchers: zinc finger nucleases (ZFNs), transcription activator-
like effectors nucleases (TALENs), and the clustered regularly interspaced short 
palindromic repeats (CRISPR), CRISPR-associated nuclease 9 (CRISPR/Cas9) (Doudna 
& Charpentier, 2014; Y. G. Kim et al., 1996; Miller et al., 2011).ZFNs are essentially 
highly-specific “genomic scissors” with two functional domains: a DNA-binding domain 
and a DNA-cleaving domain. ZFNs are able to generate gene point mutations, deletions, 
insertions, inversions, duplications, and translocations in complex genomes (Meng et al., 
2008). Currently, ZFNs still have potential to be a successful therapeutic strategy for AD 
but additional research is necessary to confirm its efficacy. One of the challenges of using 
ZFN is that the binding site of ZF and neighboring ZF moiety may affect the binding 
affinity, which makes it difficult to design ZFs that are effective and efficient. 
Additionally, the selection methods available are time consuming and labor intensive and 
thus research using ZFNs to treat AD proves to be costly as well. 
Like ZFNs, TALENs can be customized to identify and target specific DNA 
sequences. TALENs contain a domain that activates the target gene transcription, a DNA 
cleavage domain, and a nuclear localization signal. The TALEN constructs can be 
inserted into plasmids after which the target cells are transfected with plasmids, and the 
gene products enter the nucleus to access the genome. TALENs can also be delivered as 
mRNAs, but this may remove the genomic integration of the TALEN-expressing protein. 
TALEN can induce double-strand breaks (DSB) to edit genomes which are followed by 
the cell’s repair mechanisms.  TALENs may be easier to use than ZFNs and they may 
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have a higher capacity and higher rate of successfully targeting DNA compared to ZFNs 
(Reyon et al., 2012; Tran et al., 2018).  
Of the three gene editing mechanisms, CRISPR/Cas9 is dependably faster, 
cheaper, and more accurate and efficient. CRISPR/Cas9 is a revolutionary technology 
that works with a piece of RNA with a “guide” sequence that binds to a target DNA 
sequence in a genome and to a Cas9 enzyme. The RNA is used to recognize the DNA 
sequence while the Cas9 enzyme cuts the DNA at the target location. Then, the cell uses 
its repair mechanisms to add or delete genetic material or customized DNA sequences 





Figure 9. Illustration of CRISPR/Cas9 Gene Editing Technique. This schematic illustrates the potential of 
CRISPR/Cas0 to treat or cure disease. The mutation is replaced with the wild-type sequence. Step 1 shows how the 
guide RNA that matches the DNA in the genome that contains the mutation, is created. Step 2 illustrates the combining 
of the sequence with the enzyme Cas9, which cleaves both strands of the DNA double helix. Step 3 shows the guide 
RNA and Cas0 combining with the cell containing the genomic DNA. Cas0 searches the genomic DNA for the correct 
sequence using the guide RNA and then clips the targeted sequence. Step 4 shows how the cell’s repair mechanisms fix 
the break with wild-type sequence to correct the mutation (Rohn et al., 2018). 
CRISPR/Cas9 has promising potential as illustrated by its successes in addressing 
other neurological disorders, particularly Huntington disease (Shin et al., 2016; Yang et 
al., 2017). CRISPR/Cas9 also demonstrates numerous strengths, particularly its 
efficiency and capacity to target select genes, which makes it an attractive and viable 
strategy for targeting specific mutations and risk factors associated with AD. One of the 
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challenges include off-target consequences and specific cell delivery, as neuroscientists 
have to inject CRISPR into patients, enable it to cross the blood-brain barrier, target 
specific neurons, and most importantly get it into cells at the molecular level. Currently, 
there is optimism surrounding “nanocomplexes” for neurons that are used to encapsulate 
CRISPR components that turn off the BACE1 gene (Park et al., 2019). Since Bace1 is 
known to stimulate Aβ production, it serves as a key therapeutic target for in vivo gene 
editing. CRISPR-Cas9 loaded nanocomplexes injected into adult mice resulted in 
significant reduction of BACE1 and tyrosine hydroxylase (Th) compared to controls 
without other consequences such as inflammation, reactive microglia, toxicity, and 
apoptosis. Additionally, Cas9-BACE1 nanocomplexes that were injected into the CA3 
hippocampal region of 6-month-old five familial Alzheimer’s disease (5XFAD) resulted 
in 70% decrease in BACE1 expression in the CA3 region in the treated mice compared to 
controls. Β-cleavage products of APP were also reduced in the nanocomplex-treated 
5XFAD brains and the 5XFAD mice demonstrated improved cognition-related behaviors 
as observed in contextual fear conditioning, special working memory, and Morris water 
maze test.  
Additional Modalities for Alzheimer’s Treatment 
 In addition to immunotherapy and gene therapy, there are alternative treatment 
modalities targeting Aβ, tau, and dysfunction of the neural network. Aβ-targeted 
treatments aim to reduce Aβ production from APP by targeting β and γ-secretases, but 
there are some safety issues associated with these drugs. For example, γ-secretase 
physiological substrates are essential in normal biological processes, including the Notch 
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signaling protein, and so unwanted side effects may be common (Tarassishin et al., 
2004). Targeting β-Amyloid secretase inhibitor like BACE1 presents challenges like 
having a large catalytic pocket, which means the inhibitors must be large enough to 
interact within the active site, yet small enough to exhibit suitable drug-like properties 
(Vassar, 2016). Early BACE1 studies have failed to show promising results in human 
subjects and thus most of the clinical trials and research on BACE1 inhibitors have been 
paused.  
 Stem cells are another therapeutic strategy that may have potential for AD 
treatment. Stem cell strategies can include endogenous stem cell activation or stem cell 
transplantation to regenerate injured cell or tissues. Research has demonstrated that AD 
symptoms could be alleviated by transplanting stem cells from human umbilical cord, 
amnionic membrane-derived epithelial cells and mesenchyme into transgenic AD animals 
(Bae et al., 2013; Kim et al., 2012; Njie et al., 2012; H. Yang et al., 2013; Zilka et al., 
2011). Stem cell transplant showed improvement in cognition and memory and decreased 
Aβ, APP and microglia activation. While stem cells illustrate therapeutic effects, there 
are significant ethical factors that must be considered around stem cell sourcing, and 
additional research is needed to determine its appropriate application to target AD 
pathology. 
DISCUSSION 
Areas of Ongoing Research 
Substantiating treatments that target AD symptoms and pathology proves to be 
difficult largely due to multiple theories supporting the molecular mechanisms of AD. 
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Moreover, diagnosis of AD can be difficult with the variability in and subjective 
perception of individual memory loss that occurs in patients. For example, 
immunotherapy studies indicate potential to be effective in patients if treated in the very 
early stages of AD but the perception of memory loss and attribution to AD may not 
occur until symptoms progressively get worse. Without constant monitoring of AD 
biomarkers, which can be costly and cumbersome to patients, it may well be considered 
too late with currently available treatments. Access to these treatments also remains a 
highly complicated topic.  
One of the main challenges in diagnosing and providing treatment for AD earlier 
is that there is no single biomarker that can accurately diagnose AD on its own, so a 
combination of biomarkers is assessed by imaging and CSF for better diagnostic 
accuracy. Use of amyloid PET imaging and CSF biomarkers, including amyloid and tau 
deposits, help to increase diagnostic confidence in clinical trial patients, but routine use in 
clinical settings is yet uncommon due to their high cost, invasiveness, and lack of 
regulatory approval based on standardized measures. CSF biomarkers are obtained 
through invasive lumbar punctures, and there is a need for less invasive methods to 
identify diagnostic markers for early AD detection before onset of symptoms. There is 
potential to use mass spectrometry, microarrays and peptidomics to analyze circulatory 
biomarkers, blood based amyloid markers, inflammatory markers and oxidative stress 
markers which may help to predict early onset of AD and support in the delaying of 
cognitive impairment.  
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To summarize, AD treatments that target neuropathology are still theoretical and 
there is lack of support that goes beyond potential for successful treatment. Rather, there 
is a large record of clinical trials that have failed to demonstrate clinical efficacy. The 
failures in targeting Aβ has been another push in the direction to abandon the “amyloid 
hypothesis” as a model for developing AD treatment. While amyloid deposition is highly 
associated with the APOE genotype and early onset AD, amyloid deposition appears to 
begin long before symptoms of dementia become apparent. Additionally, some 
individuals with considerable amyloid burden do not develop dementia. It appears there 
must be another pathological process that directly causes dementia with amyloid 
deposition being a secondary process. When considering other genetic factors associated 
with AD aside from APOE, we notice that excess APP which is present in individuals 
with Down’s syndrome increases the risk of AD. This begs the question of understanding 
how APP is managed and involved in other potential down-stream effects aside from its 
relation to Aβ. 
Public Health Implications 
 AD’s strong genetic component indicates that genetics plays a significant role in 
AD onset. This highlights the potential to track genetic markers and measure the risk, to 
some extent, of developing AD to inform intervention and mitigation strategies. One 
convenient way of detecting such genetic markers is through a direct-to-consumer genetic 
testing service called 23andMe, that has continuously risen in popularity over recent 
years. At $199, 23andMe provides a “Health + Ancestry Service” that includes a health 
predisposition report which allows users to opt in to receive a Late-Onset Alzheimer’s 
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Disease genetic health risk report. This reports the APOE variants to describe if an 
individual has a variant associated with an increased risk of developing late-onset AD, 
but does not describe the overall risk of developing AD (23andMe, n.d.). Individuals who 
opt in to receive the report can find out the number of APOEε4 alleles they have, which 
only tells them that they either do or do not have copies of the allele, and that their risk 
for developing AD will increase with the more copies they have. This method is a 
relatively easy way to find out if individuals are predisposed to developing AD, however 
it is highly inconclusive and does not lead to any actionable steps for individuals who 
find out they have APOEε4 variants. Results may increase stress among individuals who 
test positive for APOEε4. On the other hand, one can speculate that this may also lead to 
desire among select individuals to participate in research studies or find alternative ways 
to measure potential risk for AD and related cognitive decline. This acts as an advantage 
for individuals who may be able to find out their predispositions earlier and potentially 
undergo additional tests and monitoring to determine AD onset, and it poses a public 
health question around who should have access to this type of early indicators. While 
23andMe is not a diagnostic test and thus not covered by insurance, it still provides 
marginal benefit to those who have the means to purchase a kit. This begs additional 
discussion around social determinants of health and the socioeconomic impact on 
individuals’ likelihood to be diagnosed with AD earlier and thus can mitigate the 
symptoms of AD earlier.  
In 2018, 23andMe signed a four-year $300 million deal with GlaxoSmithKline 
that allows GlaxoSmithKline access to DNA results of millions of customers of 23andMe 
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who opted in to participate in scientific research, paving way to use the results in the field 
of active drug discovery research. This partnership will prove interesting as it gives 
Glaxo exclusive rights to collaborate with 23andMe to develop drugs. It can be 
speculated that analysis is of millions of customers’ data could reveal relationships 
between APOEε4 and other genetic markers, that may ignite additional research on AD 
development in presence of APOEε4 and those other genetic markers. Future research 
and testing will undoubtedly be required to reveal any implications for developing 
pharmacologic therapies for AD with 23andMe data.  
 Lifestyle factors that could help reduce the risk of late-onset AD development 
include healthy diet that includes leafy vegetables, fruits, and whole grains, cognitive 
stimulation that promotes brain health, and exercise. To add to these lifestyle factors, 
there are socio-environmental factors that may be at play in dementia etiology. While a 
systematic review and meta-analysis demonstrated that numerous studies reported higher 
prevalence of dementia in rural communities, this reliance on cross-sectional data from 
the prevalence studies was not able to account for individuals with AD selectively 
migrating to care homes which are typically located outside of cities and in more rural 
areas (Russ et al., 2012). Additionally, the studies that track incidence do not factor in the 
environmental influences that may have played a role prior to diagnosis.  Contrary to 
findings from cross-sectional data, a multilevel longitudinal analysis of 261,669 
participants, tracked by incidence of AD defined by first cholinesterase inhibitor 
prescription and records from the Department of Human Services in Australia, show AD 
risk was lower in “outer regional and remote areas” compared with “major cities” (Astell-
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Burt & Feng, 2018). The individuals from this study who lived in major cities appear to 
have higher risk of developing AD when compared to their counterparts who live outside 
of major cities. Findings from this study suggest differential exposure to certain 
environmental factors such as air pollution, noise, availability of green space, and their 
consequent effects on stress and physical activity may influence an individual’s risk of 
developing AD. For example, other studies suggest air pollution, namely toxic 
environmental compounds such as metals, nanoparticles and pesticides may increase the 
risk of AD by generating oxidative stress (Chin-Chan et al., 2015). A more recent study 
has also suggested that availability of green space in early life may play a protective role 
in cognitive aging, especially in women, people without an APOEe4 allele, and in lower 
socioeconomic groups in adulthood (Cherrie et al., 2018). One of the existing challenges 
is identifying biomarkers to determine past exposure to environmental pollutants to better 
interfere and manage AD. Interestingly, a large population cohort study has shown an 
association between living close to heavy traffic areas and higher incidence of dementia, 
but not Parkinson’s disease or multiple sclerosis, after adjusting for air pollution as well 
as individual factors including diabetes, brain injury and neighborhood income, and 
restricting to never movers and urban dwellers (Chen et al., 2017). Additional evidence 
suggests long term co-exposure of air pollution and road traffic noise may act 
synergistically on cognitive function in adults (Tzivian et al., 2017). Thus, there is 
anticipation for improved epidemiological studies that can improve quality of life in the 
elderly and prevent neurodegenerative diseases. While additional research is warranted, 
the general effects of these socio-environmental determinants of health have implications 
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on policy and its impact in protecting public health. Particularly, emphasizing the need to 
provide access to parks and green spaces throughout individuals’ lifetimes, from 
childhood to adulthood and educating and advocating their use may improve cognitive 
wellbeing in later adulthood.  
CONCLUSIONS 
One of the key challenges in determining the cause of AD is the difficulty in 
separating causation from correlation especially given the gradual of AD development. 
Moreover, determining the specific causes by observing AD patients requires long-term 
observation of individuals as well as normal subjects with various control factors put in 
place which may be difficult. Longitudinal studies are essential to corroborate existing 
findings and shed new light on the socio-environmental factors that contribute to AD. 
Particularly, these types of longitudinal studies in conjunction with ongoing large 
GWASs may illuminate connections between genetic variants as well as socio-
environmental factors. Currently, the world’s largest GWAS, the European Alzheimer 
DNA Biobank project, has been launched with 38,000 AD cases and 60,000 control 
participants. Additionally, the Alzheimer’s Disease Genetics Consortium is designing 
large studies of African-American and Caribbean populations in the U.S. There are also 
large sequencing projects that are proceeding in various ethnic groups. One of the 
challenges in analyzing these studies will be to adopt a hypothesis-free approach, 
independent of existing knowledge, to avoid retrofitting findings and newly identified 
genes into processes that are already thought to be involved in AD. This will enable a 
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more holistic approach which will confirm the mechanisms that have acknowledged by 
the scientific community or highlight new processes.   
Currently, gene editing appears to show the most potential for successfully and 
effectively treating AD. While ZF is an older technology, CRISPR is the most discussed 
in the field as a cheap and efficient gene editing method, competing with ZF in striving to 
find clinical applications for AD. Nevertheless, there is a lot of hope and ongoing 
research around both methods. For example in 2020, Cambridge, MA- based company 
Biogen paid the biotech firm Sangamo $350 million to develop ZF gene therapies for 
AD, Parkinson’s, and neuromuscular diseases (Biogen Bets Big on Sangamo’s Zinc 
Fingers to Treat Alzheimer’s, n.d.). Sangamo’s ZF technology focuses on altering the 
expression of existing genes that are linked to disease rather than introducing new genetic 
material. The ZF proteins are designed to target and bind to a specific DNA sequence 
without cutting it, and then it attaches transcription factor to turn the gene on or off. The 
company hopes that the resulting zinc finger protein transcription factor (ZFP-TF) will 
stop the production of proteins strongly associated with neurological diseases. For 
example, the partnership program’s ZFP-TF is designed to reduce levels of tau and 
Sangamo has demonstrated its success in reducing levels of all types of tau in rodent and 
monkey brains. Additionally, companies are exploring the viability of using AAV to 
deliver genes encoding ZFP-TFs in neurons. Demand is growing for novel AAV variants 
that can better deliver the chosen genetic material into specific cell types in targeted areas 
of the brain affected by AD. One of the challenges that scientists, physicians, biotech and 
healthcare companies will face is answering the question of who can be treated, when, 
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and how gene modification will be paid for, as gene modification is still considerably 
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